The Global Regenerative Medicine Market is likely to expand considerably in the coming years due to growing applications in the treatment of chronic diseases. According to a report published by Fortune Business Insights, titled “Regenerative Medicine: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 23,841.5 Mn in 2018.
Key players leading the Global Regenerative Medicine Market include
- Integra LifeSciences Corporation,
- CELGENE CORPORATION,
- American CryoStem Corporation,
- Tissue Regenix,
- Avita Medical,
- Osiris Therapeutics, Inc.,
- Wright Medical Group N.V.,
- Smith & Nephew,
- Integra LifeSciences Corporation.
Fortune Business Insights states that The Regenerative Medicine Market will reach US$ 151,949.5 Mn by the end of 2026, thereby exhibiting a CAGR of 26.1%.
Integra LifeSciences’ Latest Product Offering Will Favor Market Growth
The advancements in regenerative medicine have fueled their demand across the world. Increasing product launches have contributed to the rising uptake of regenerative medicine across the world. In 2017, Integra LifeSciences announced the launch of Integra Dermal Regeneration Template Single Layer ‘Thin’. The product was aimed at repairing dermal defects in a one-step procedure. The medicine will also aid in reducing hospital stays. Fortune Business Insights has identified Integra’s latest product offering as a major market growth driver. The report includes product launches, similar to Integra’s latest medicine and gauges the impact of these products on the global regenerative medicine Industry in the coming years.
Novartis Receives EU Approval for Luxturna
The severity of chronic diseases has led to the demand for efficient medicines. The ability of regenerative medicine to treat severe life-threatening diseases in an efficient manner has created a huge demand for the products across the world. Increasing drug approvals have contributed to the rising uptake for regenerative medicines. In 2018, Novartis received usage approval from the European Union for its latest regenerative medicine ‘Luxturna’. The drug was used to treat and restore sight for people with vision impairment. Luxturna was widely useful in treatment of rare retinal diseases. Fortune Business Insights states that the approval for Luxturna will contribute to the growth of the global regenerative medicine market in the forthcoming years.
- Cell Therapy
- Gene Therapy
- Tissue Engineering
- Platelet Rich Plasma
- Wound Care
By Distribution Channel
More Trending Topics From Fortune Business [email protected]